Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

AIDS

Volumn 30, Issue 9, 2016, Pages 1385-1392

  Gutiérrez, Carolina ^a   Serrano Villar, Sergio ^a   Madrid Elena, Nadia ^a   Pérez Eĺas, Maria J ^a   Martń, Maria Elena ^a   Barbas, Coral ^b   Ruipérez, Javier ^b   Muñoz, Eduardo ^c   Muñoz Fernández, Maria Angeles ^d   Castor, Trevor ^e   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e Aphios Corporation   (United States)

Author keywords

Bryostatin 1; HIV eradication; HIV 1 reactivation; HIV latency; Protein kinase C; Reservoirs

Indexed keywords

BRYOSTATIN 1; CD14 ANTIGEN; INTERLEUKIN 6; PLACEBO; PROTEIN KINASE C; VIRUS RNA; ANTIRETROVIRUS AGENT; BRYOSTATIN; ENZYME ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LATENT VIRUS INFECTION; LIMIT OF DETECTION; MYALGIA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; VIREMIA; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; ADULT; ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; BRYOSTATINS; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME ACTIVATORS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; TREATMENT OUTCOME; VIRUS LATENCY;

EID: 84958793805     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001064     Document Type: Article

References (33)

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presenceof aninducibleHIV-1 latent reservoirduringhighly active antiretroviral therapy. PNAS 1997; 94:13193-13197.
2. Chun TW, Carruth L, Finzi D, Shen X, Digiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
4. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-593.
5. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
6. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2013; 18 (11-12):541-551.
7. ArchinNM, Liberty L,KashubaD,Choudhary SK,Kuruc JD, Crooks M, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
8. Rasmussen T, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1:e1413-21.
9. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004473.
10. Zhang X, Zhang R, Zhao Cai H, Gush K, Kerr RG, et al. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 1996; 56:802-808.
11. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 2003; 14:1607-1615.
12. Pérez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Muñoz-Fernandez MA, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8:418-429.
13. Plimack ER, Tan T, Wong Y-N, von Mehren MM, Malizzia L, Roethke SK, et al. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. Oncologist 2014; 19:354-355.
14. Morgan RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, et al. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs 2012; 30:723-728.
15. Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, et al. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res 2011; 35:87-94.
16. Pavlick AC,Wu J, Roberts J, Rosenthal M, Hamilton A,Wadler S, et al. Phase I study of bryostatin-1, a protein kinase C modulator, preceding cisplatin in patients with refractory nonhematologic tumors. Cancer Chemother Pharmacol 2009; 64:803-810.
17. Ajani J, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, et al. A multicenter phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 2006; 24:353-357.
18. Zhao M, Rudek M, He P, Smith BD, Baker SD. Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. Anal Biochem 2005; 337:143-148.
19. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 2010; 5:e11160.
20. Martńez-Bonet M, Clemente MI, Á lvarez S, Dáz L, Garća-Alonso D, Muñoz E, et al. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antiviral Res 2015; 123:163-171.
21. Dáz L, Martńez-Bonet M, Sánchez J, Fernández-Pineda A, Jiménez JL, Muñoz E, et al. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kBdependent mechanism. Sci Rep 2015; 5:12442.
22. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-429.
23. LairdGM,BullenCK,RosenbloomDIS,MartinAR,HillAL, Durand CM, et al. Ex vivo analysis identifies effective HIV-1 latencyreversing drug combinations. J Clin Invest 2015; 125:1901-1912.
24. El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 2006; 12:7059-7062.
25. Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999; 73:6099-6103.
26. Fischer M, Huber W, Kallivroussis A, Ott P, Opravil M, Lüthy R, et al. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol 1999; 37:1260-1264.
27. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561.
28. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16:56-62.
29. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS. Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood 1990; 75:1319-1323.
30. Archin NM, Bateson R, Tripathy M, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J Infect Dis 2014; 210:728-735.
31. Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 2015; 11:e1005142.
32. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot J-S, Quivy V, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093.
33. Martńet-Bonet M, Clemente I, Serraḿa MJ, Muñoz E, Moreno S, Muñoz-Fernández MA. Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Sci Rep 2015; 13:16445.